TG Therapeutics Inc (TGTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TG Therapeutics Inc (TGTX) has a cash flow conversion efficiency ratio of 0.035x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($21.37 Million) by net assets ($604.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TGTX market cap for the company's overall valuation and market capitalisation.
TG Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how TG Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
TG Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TG Therapeutics Inc ranked by their cash flow conversion efficiency. Explore TG Therapeutics Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AU Small Finance Bank Limited
NSE:AUBANK
|
-0.363x |
|
Piraeus Financial Holdings S.A
AT:TPEIR
|
0.109x |
|
Turkish Airlines
IS:THYAO
|
0.050x |
|
Fiberhome Telecommunication Technologies Co Ltd
SHG:600498
|
0.032x |
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
-0.159x |
|
Jiangsu Yanghe Brewery Joint-Stock Co Ltd
SHE:002304
|
0.010x |
|
Banca Transilvania S.A.
RO:TLV
|
0.028x |
|
Redeia Corporacion S.A.
MC:RED
|
0.064x |
Annual Cash Flow Conversion Efficiency for TG Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of TG Therapeutics Inc from 1996 to 2025. View TGTX live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $648.02 Million | $-24.77 Million | -0.038x | +79.02% |
| 2024-12-31 | $222.36 Million | $-40.52 Million | -0.182x | +6.90% |
| 2023-12-31 | $160.50 Million | $-31.41 Million | -0.196x | +93.49% |
| 2022-12-31 | $58.59 Million | $-176.17 Million | -3.007x | -141.22% |
| 2021-12-31 | $237.15 Million | $-295.63 Million | -1.247x | -201.82% |
| 2020-12-31 | $519.35 Million | $-214.51 Million | -0.413x | +87.99% |
| 2019-12-31 | $38.62 Million | $-132.81 Million | -3.439x | +35.88% |
| 2018-12-31 | $24.04 Million | $-128.93 Million | -5.364x | -- |
| 2017-12-31 | $0.00 | $-93.76 Million | x | -- |
| 2016-12-31 | $0.00 | $-61.59 Million | x | -- |
| 2015-12-31 | $0.00 | $-44.69 Million | x | -- |
| 2014-12-31 | $0.00 | $-35.06 Million | x | -- |
| 2013-12-31 | $0.00 | $-10.82 Million | x | -- |
| 2012-12-31 | $15.55 Million | $-5.19 Million | -0.334x | -3613.31% |
| 2011-12-31 | $9.64 Million | $-86.58K | -0.009x | -102.45% |
| 2010-12-31 | $-5.36 Million | $-1.97 Million | 0.367x | +137.37% |
| 2009-12-31 | $-6.78 Million | $-1.05 Million | 0.155x | -84.76% |
| 2008-12-31 | $-4.38 Million | $-4.44 Million | 1.016x | -91.15% |
| 2007-12-31 | $-891.09K | $-10.23 Million | 11.480x | +322.86% |
| 2006-12-31 | $1.50 Million | $-7.75 Million | -5.151x | -686.97% |
| 2005-12-31 | $9.54 Million | $-6.24 Million | -0.655x | +48.77% |
| 2004-12-31 | $4.45 Million | $-5.69 Million | -1.278x | -152.94% |
| 2003-12-31 | $6.83 Million | $-3.45 Million | -0.505x | -111.53% |
| 2002-12-31 | $-326.99K | $-1.43 Million | 4.381x | +222.37% |
| 2001-12-31 | $1.25 Million | $-4.47 Million | -3.580x | -240.33% |
| 2000-12-31 | $1.10 Million | $-1.15 Million | -1.052x | -55.51% |
| 1999-12-31 | $3.40 Million | $-2.30 Million | -0.676x | -53.51% |
| 1998-12-31 | $5.90 Million | $-2.60 Million | -0.441x | +9.71% |
| 1997-12-31 | $8.40 Million | $-4.10 Million | -0.488x | +74.37% |
| 1996-12-31 | $2.10 Million | $-4.00 Million | -1.905x | -- |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolat… Read more